Lassa fever research priorities: towards effective medical countermeasures by the end of the decade.

Autor:	Moore KA; Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis, MN, USA. Electronic address: kamoore@umn.edu., Ostrowsky JT; Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis, MN, USA., Mehr AJ; Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis, MN, USA., Johnson RA; Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis, MN, USA., Ulrich AK; Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis, MN, USA., Moua NM; Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis, MN, USA., Fay PC; Infectious Disease Strategic Programme, Wellcome Trust, London, UK., Hart PJ; Infectious Disease Strategic Programme, Wellcome Trust, London, UK., Golding JP; Infectious Disease Strategic Programme, Wellcome Trust, London, UK., Benassi V; World Health Organization, Geneva, Switzerland., Preziosi MP; World Health Organization, Geneva, Switzerland., Adetifa IM; Nigeria Centre for Disease Control & Prevention, Abuja, Nigeria., Akpede GO; Ambrose Alli University, Ekpoma, Nigeria; Institute of Viral and Emergent Pathogens Control and Research (formerly, Institute of Lassa Fever Research and Control), Irrua Specialist Teaching Hospital, Irrua, Nigeria., Ampofo WK; University of Ghana, Accra, Ghana., Asogun DA; Irrua Specialist Teaching Hospital, Irrua, Nigeria., Barrett ADT; Sealy Institute for Vaccine Sciences and Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA., Bausch DG; FIND, Geneva, Switzerland; Department of Disease Control, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK., de Coster I; Centre for the Evaluation of Vaccination, University of Antwerp, Antwerp, Belgium., Emperador DM; FIND, Geneva, Switzerland., Feldmann H; Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA., Fichet-Calvet E; Bernhard-Nocht Institute for Tropical Medicine, Hamburg, Germany., Formenty PBH; World Health Organization, Geneva, Switzerland., Garry RF; Tulane University, New Orleans, LA, USA; Zalgen Labs, Frederick, MD, USA; Global Viral Network, Baltimore, MD, USA., Grant DS; Kenema Government Hospital, Ministry of Health and Sanitation, Freetown, Sierra Leone; College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone., Günther S; Bernhard-Nocht Institute for Tropical Medicine, Hamburg, Germany., Gupta SB; lnternational AIDS Vaccine Initiative, New York, NY, USA., Jaspard M; The Alliance for International Medical Action, Dakar, Senegal; Saint-Antoine Hospital, Infectious Disease Department, Assistance Publique-Hôpitaux de Paris, Paris, France; INSERM Unit 1136 Institut Pierre Louis D'Epidémiologie et de Sante Publique, Paris, France., Mazzola LT; FIND, Geneva, Switzerland., Okogbenin SA; Irrua Specialist Teaching Hospital, Irrua, Nigeria., Roth C; UK Foreign, Commonwealth and Development Office, London, UK., Schmaljohn CS; Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, Frederick, Maryland, USA., Osterholm MT; Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis, MN, USA.
Jazyk:	angličtina
Zdroj:	The Lancet. Infectious diseases [Lancet Infect Dis] 2024 Nov; Vol. 24 (11), pp. e696-e706. Date of Electronic Publication: 2024 Jul 01.
DOI:	10.1016/S1473-3099(24)00229-9
Abstrakt:	In 2016, WHO designated Lassa fever a priority disease for epidemic preparedness as part of the WHO Blueprint for Action to Prevent Epidemics. One aspect of preparedness is to promote development of effective medical countermeasures (ie, diagnostics, therapeutics, and vaccines) against Lassa fever. Diagnostic testing for Lassa fever has important limitations and key advancements are needed to ensure rapid and accurate diagnosis. Additionally, the only treatment available for Lassa fever is ribavirin, but controversy exists regarding its effectiveness. Finally, no licensed vaccines are available for the prevention and control of Lassa fever. Ongoing epidemiological and behavioural studies are also crucial in providing actionable information for medical countermeasure development, use, and effectiveness in preventing and treating Lassa fever. This Personal View provides current research priorities for development of Lassa fever medical countermeasures based on literature published primarily in the last 5 years and consensus opinion of 20 subject matter experts with broad experience in public health or the development of diagnostics, therapeutics, and vaccines for Lassa fever. These priorities provide an important framework to ensure that Lassa fever medical countermeasures are developed and readily available for use in endemic and at-risk areas by the end of the decade. Competing Interests: Declaration of interests KAM, AJM, NMM, JTO, MTO, and AKU declare receiving financial support for the completion of this Personal View from Wellcome (grant number 226538/Z/22/Z), payments were made to the University of Minnesota. ADTB is a member of the Vaccine Research, Development and Manufacturing Committee of the Coalition for Epidemic Preparedness Innovations (CEPI). DME is employed by FIND. RFG declares grants U01AI151812, U19AI135995, R01AI132223, R01AI132244, and U19AI142790, all awarded from the National Institute of Allergy and Infectious Diseases, LEAP4WA awarded by the European & Developing Countries Clinical Trials Partnership, and ESEP1904 and INTU1901, both awarded by CEPI; stocks in and royalties or licenses from Zalgen Labs; ownership of a monoclonal antibody patent (WO2018106712A1); and travel support from Wellcome to attend the workshop identified in this Personal View. SG declares financial support for this Personal View from WHO and Wellcome; the receipt of drugs for clinical trials from Toyama–Fujifilm; grants (all payments were made to SG's institutions) from the German Research Foundation (grants GU 883/4-2, GU 883/5-1, and GU 883/7-1), the European Commission (project 101103204—INTEGRATE), the German Government, Ministry of Health (projects ZMI1-2521WHO002 and ZMII2-2523GHP006), CEPI (framework agreement for implementing partner services); the Kirmser Foundation (donation of equipment); speaker honoraria for continuing medical education on viral haemorrhagic fevers; and support for attending meetings from WHO, Wellcome, and CEPI, including travel support from Wellcome to attend the workshop identified in this Personal View. LTM declares being a science consultant at FIND, for which she receives grants, contracts, and consulting fees; and travel support from Wellcome to attend the workshop identified in this Personal View. SAO declares a consulting contract with CEPI (payments made to SAO); is a member of the INTEGRATE consortium with grants from the European & Developing Countries Clinical Trials Partnership (payments made to SAO's institution); and support from CEPI and EDCTP funds (payments made to travel agencies and through SAO's institution). CR declares participation on a Data Safety Monitoring Board or Advisory Board (this advisory board was designated after CR's participation in the work leading to this Personal View). WKA is Executive Director of the African Vaccine Manufacturing Initiative, and Cheif Executive of National Vaccine Institute, Ghana. DAA, IMA, WKA, ADTB, DGB, EF-C, IdC, DSG, SBG, MJ, KAM, JTO, MTO, AKU, and CSS declare Wellcome supported for travel to attend the workshop identified in this Personal View. PCF, PJH, and JPG worked at Wellcome during the time that this Personal View was completed. All other authors declare no competing interests. No authors were paid by a pharmaceutical company or any other agency to write this Personal View. The authors alone are responsible for the views expressed in this Personal View and they do not necessarily represent the views, decisions, or policies of the institutions with which they are affiliated. Editorial note: The Lancet Group takes a neutral position with respect to territorial claims in published maps and institutional affiliations. (Copyright © 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu